Here, we show that Amuvatinib selectively inhibits cell proliferation in βIII‐tubulin supressed cells by disrupting MAPK signalling downstream of c‐Met, highlighting a novel approach for targeting this important signalling axis in NSCLC. This evidence concerns the gene MET and non-small cell lung carcinoma.